STOCKS TELEGRAPH

Author: Hassan Masood

  • Here’s the Reason Why Paratek Pharmaceuticals, Inc. (PRTK) Stock is Soaring in Aftermarket

    Here’s the Reason Why Paratek Pharmaceuticals, Inc. (PRTK) Stock is Soaring in Aftermarket

    Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company, has surged 7.30% in aftermarket trading session. Consequently, PRTK stock is trading at $4.70 at the time of the writing. The speculations regarding the approval of NUZYRA (omadacycline), a novel antibiotic being produced by the company, in China have catalyzed the movement of stock. On Friday, PRTK stock closed the day at $4.38 after declining 2.23% during regular trading hours.

    PRTK Q3 2021 Operational Results

    On 8th November, PRTK released the financial and operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company had cash and cash equivalents of $110.99 million on 30th September. The total revenue generated by the company during the period was $3.01 million against $1.86 million for the same period of 2020. The total operating expenses bore by the company during the period were $38.16 million against $29.60 million for the same period of 2020. The net loss suffered by the company during the quarter stood at $18.2 million against $20.8 million for the same quarter of 2020.

    Financial Guidance for Upcoming Period

    Alongside the operational results, PRTK also updated its financial guidance for the upcoming period. The company anticipated that the net revenue of NUZYRA would be at the higher end of the previously estimated range of $100 to $106 million. That would include the $38 million NUZYRA procurement by BARDA which happened during June 2021. The total revenue was expected to be in the range of $128 million to $139 million. The total expenses were projected to be within the range of $150 to $155 million.

    Executive Commentary

    Evan Loh, M.D., chief executive officer of PRTK, while commenting on the results said that the company is extremely proud of the 30% quarter over quarter growth in its core business despite continually facing challenges from the ongoing pandemic. He hoped that the company would carry the momentum forward which it attained through continued execution of its strategic policies.

    Future Outlook for PRTK

    Despite the association of numerous positive sentiments with it, PRTK stock doesn’t look in great shape. The stock has declined by more than 45% during the last 6 months. But the more recent performance is depicting a change in fortunes for PRTK stock. Hence, potential investors should keep a close eye on the stock.

  • Datasea Inc. (DTSS) Stock Declining in Aftermarket, Here’s the Reason

    Datasea Inc. (DTSS) Stock Declining in Aftermarket, Here’s the Reason

    Datasea Inc. (DTSS), a company that provides smart security solutions in the People’s Republic of China, has declined 5.26% in aftermarket trading session. As a result, DTSS stock is trading at $1.62 at the time of the writing. The decline could be attributed to short selling by certain investors. On Friday, DTSS closed the day at $1.71 after increasing 1.79% during regular trading hours. Ler’s discuss recent developments related to DTSS stock.

    Procurement Contract with Hangzhou Shuhai Zhangxun

    On 18th November, DTSS announced that its wholly-owned subsidiary, by the name of Hangzhou Shuhai Zhangxun Information Technology Co., Ltd. had entered into a $378k procurement contract with the China Mobile Group Guangdong Co., Ltd. for the cloud transformation services. The company would provide hardware and software to China Mobile after the contract has taken place. The cloud services would include cloud computing, cloud database and cloud network offering.

    DTSS Presentation

    On 15th November, DTSS announced that it would give a presentation at the Q4 virtual investor summit. The management team of the company was to provide an overall view of the company business during the presentation. The presentation was also to include an update on the critical strategic and operational initiatives undertaken by the company. Zhixin Liu, CEO of Datasea commented on the development that the company s fusing its business goals into its each business decision, which in turn focuses on the long-term establishment of business advantages.

    Procurement Contract with Jiangxi Zhouwang

    On 18th October, DTSS announced that its wholly-owned subsidiary, namely Shuhai Zhangxun Information Technology Co., Ltd., had signed a $4.67 million procurement contract for the short message and 5G multimedia message services with Jiangxi Zhouwang Network Technology Co., Ltd. As a result of the contract, DTSS subsidiary Shuhai Zhangxun was to provide help to Jiangxi Zhouwang to reach its clients as well as provide the value-added telecommunication messaging services. The term of the contract is placed at one year.

    Future Outlook for DTSS

    The recent few months have proven to be a hard time for DTSS stock as it has continually faced a declining trend. During the last six months, DTSS stock has declined more than 30%. However, analysts are hopeful that the business expansion strategies adopted by the company could serve as a stimulus for the growth of DTSS stock in the future.

  • Dermata Therapeutics Inc. (DRMA) Stock Surging in Aftermarket, Here’s the Reason

    Dermata Therapeutics Inc. (DRMA) Stock Surging in Aftermarket, Here’s the Reason

    Dermata Therapeutics Inc. (DRMA), a clinical-stage biotechnology company, has surged 8.52% on aftermarket trading session. As a result, DRMA stock is trading at $2.93 at the time of the writing. Analysts have attributed this rise to insider buying as the major owner of the company, Proehl Gerald, picked up 20,000 shares at a common stock price of $2.4 per share. On Friday, DRMA closed the day at $2.70 after declining 3.91% during regular trading hours. For the moment, let’s discuss recent developments of DRMA.

    DRMA Q3 2021 Operational Results

    On 16th November, DRMA released the operational and financial results for the third quarter of the fiscal year 2021. The quarter ended on 30th September. The company had cash of $12.6 million on 30th September 2021. The total operating expenses bore by the company during the period were $1.71 million against $0.54 million for the same period of 2020. The net loss suffered by the company during the three month period stood at $1.71 million against $0.59 million for the same period of 2020. The net loss per basic and diluted share for the period was $0.86 against $0.31 for the same period of 2020.

    Corporate Highlights

    Alongside the financial results, DRMA also shed a light on its corporate highlights. The company announced positive topline results from phase-1b POC Clinical Trial of DMT310 in Mild-to-moderate Psoriasis in late October. In August, it closed upsized $18 million initial Public Offering on Nasdaq Capital Market. It expanded its board of directors by appointing four experienced life sciences leaders to its BoD. In early September, it expanded its executive team by appointing Kyri Van Hoose as Chief Financial Officer.

    Executive Commentary

    Gerry Proehl, Chairman, President and Chief Executive Officer of DRMA, while commenting on the results said that the third quarter has proved to be a transformation for the company as it completed its IPO during the period. He hoped that in the future, the company would carry the momentum forward from its brilliantly ongoing studies and from the financial results it has achieved so far.

    Future Outlook for DRMA

    Analysts have predicted that DRMA is well on the track to achieve financial success in the upcoming quarters, as by then it would be able to achieve meets the targets that it has set for itself. So, a potential investor should closely keep watching the fluctuation of DRMA stock.

  • Theravance Biopharma, Inc. (TBPH) Stock Consistently Declining, Here’s Why

    Theravance Biopharma, Inc. (TBPH) Stock Consistently Declining, Here’s Why

    Theravance Biopharma, Inc. (TBPH), a diversified biopharmaceutical company, has declined 5.24% in aftermarket trading session. Consequently, TBPH stock is trading at $7.59 at the time of the writing. On Friday, TBPH closed the day $8.01 after declining 5.21% during regular trading hours. The uncertainty regarding clinical trials being performed by the company has made the stock decline continuously during the last few months.

    TBPH Q3 2021 Operational Results

    On 3rd November, TBPH reported the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $13.19 million against $18.25 million for the same period of 2020. The total costs and expenses bore by the company during the three months was $66.80 million against $94.87 million for the same period of 2020. The net loss suffered by the company during the three months stood at $35.30 million ($0.48 per basic and diluted share) against $73.64 million ($1.16 per basic and diluted share) for the same period of 2020

    Financial Guidance for Upcoming Period

    TBPH also updated the financial guidance for the complete year 2021. The company expected that the Research and Development expenses for the full year 2021 would stand at $180 million to $190 million. Alongside, there was an expectation that the Selling, General, and Administrative expenses for the full year 2021 would stand in the range of $70 million to $80 million.

    Executive Commentary

    Rick E Winningham, Chief Executive Officer of TBPH, while commenting on the results said that the quarter under discussion was about executing its strategies to create and implement a new business model. He said that the company is executing against the strategic plan it announced during the mid of September. He said that the focus of the company is on driving the growth of YUPELRI, streamlining R&D investment, and optimizing its asset portfolio to maximize shareholder value.

    Future Outlook for TBPH

    During the last 6 months, TBPH has declined more than 50%. The prime reason for that could be the negative sentiments associated with stock throughout the period due to the effects the pandemic imparted throughout the period. However, the analysts are hopeful that going forward, the stock is in a good shape to pay back the shareholders with benefits.

  • IT Tech Packaging, Inc. (ITP) Stock on Decline in Aftermarket Despite no Obvious Stimulant

    IT Tech Packaging, Inc. (ITP), a company that produces and distributes paper products in China, has declined 5.17% in aftermarket trading session. As a result, ITP stock is trading at $0.32 at the time of the writing. There was no obvious reason for the decline except for the fact that the harsh policies by Chinese regulators are proving pernicious for Chinese stocks. On Thursday, ITP closed the day at $0.34 after increasing 1.19% during regular trading hours. Let’s discuss some recent developments related to ITP stock.

    ITP Q3 2021 Financial Results

    On 10th November, ITP released the financial results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company had a cash and bank balance of $26.57 million on 30th September 2021. The revenue generated by the company during the period was $45.08 million against $33.35 million for the same period of 2020. The Selling, General, and Administrative expenses for the period were $2.01 million against $2.39 million for the same period of 2020. The net income generated by the company during the quarter was $1.54 million against $0.52 million for the same period of 2020. The net income per share for the three months was $0.03 against the net loss of $0.02 per basic and diluted share for the same three-month period of 2020.

    Business Highlights

    Alongside the financial results, ITP also reported the recent business highlights. The company announced the approval for surgical mask products from US FDA on 26th May 2021. The company also showed results for the required period to the public. On 6th July, the company announced that its tissue paper research and development centre had received a Level B scale-above Certification as an industrial R&D enterprise institution in Hebei province after the on-site inspection by regulators.

    Executive Commentary

    Mr. Zhenyong Liu, Chairman and Chief Executive Officer of ITP, while commenting on the results said that the company is continually making improvements in its sales sector. He said that the total revenue generated during the first nine months of the fiscal year has increased by approximately 70%. He hoped that the company would be much better in the upcoming quarters.

    Future Outlook for ITP

    The last 12 months have seen ITP stock decline by about 50%. The reason was the uncertainty associated with the stock for its tussle with FDA. However, as the company has been granted FDA approval recently, ITP stock is on track to rise extraordinarily in the coming weeks.

  • Cars.com, LLC (CARS) Stock on a Surge in Aftermarket, Here’s the Reason

    Cars.com, LLC (CARS), a company that operates as a digital marketplace, and provides solutions for the automotive industry, has surged 9.69% in aftermarket trading session. Consequently, CARS stock is trading at $14.60 at the time of the writing. The increase was attributable to the addition of the company in S&P SmallCap 600. On Thursday, CARS closed the day at $13.31 after gaining a slight increase of 0.075% during regular trading hours.

    Why CARS Stock Surging?

    On Thursday, CARS announced that it would replace DSP Group Inc. (DSPG) in the S&P SmallCap 600. The move came after it was announced by Synaptics Inc. (SYNP) that it would be acquiring DSPG in a deal that would be expected to complete on 2nd December 2021. As a result, the replacement of CARS with DSPG in S&P SmallCap 600 would complete on 2nd December as well.

    Q3 2021 Financial Results

    On 4th November, CARS reported the financial results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $156.55 million during the quarter against $144.39 million for the same period of 2020. The total operating expenses bore by the company during the period were $144.47 million against $125.32 million for the same period of 2020. The net income generated by the company during the period was $2.43 million (or $0.04 and $0.03 per basic and diluted share respectively) against the net loss of $12.26 million (or $0.18 per basic and diluted share) for the same period of 2020.

    Executive Commentary

    Alex Vetter, President and Chief Executive Officer of CARS, while commenting on the results said that the company’s revenue continues to grow along a steep trajectory. He assured shareholders that going forward; the company hopes to strengthen the capabilities of its platforms as it continually looks to bring expansion into its business model.

    Future Outlook for CARS

    The last few months have seen a steady increase in the value of CARS stock. The stock has increased by more than 10% during the last three months. On a broader scale, however, the last one and a half years have not proved excellent for CARS as the pandemic was wreaking havoc. However, the company believes that the recent performance would build investor confidence in the company.

  • Want to Know Why Aeterna Zentaris Inc. (AEZS) Stock is on a Rally, Here’s Your Answer

    Aeterna Zentaris Inc. (AEZS), a specialty biopharmaceutical company, has gained a monumental increase of 5.65% in aftermarket trading session. As a result, AEZS stock is trading at $0.52 at the time of the writing. On Thursday, AEZS closed the day at $0.49 after increasing 4.66% during regular trading hours. The increase has come despite no apparent news or press release which could have prompted that. So for the moment, let’s discuss its recent developments.

    AEZS Q3 2021 Operational Results

    On 4th November, AEZS released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September 2021. The company generated total revenue of $0.6 million during the quarter against $0.1 million for the same period of 2020. The total operating expenses bore by the company during the quarter were $2.4 million against $1.9 million for the same quarter of 2020. The net finance income generated by the company during the period was $0.1 million against $0.6 million for the same period of 2020. The consolidated net loss suffered by the company during the period was $1.7 million (or $0.01 per common share) against $0.01 per common share) against $11 million (or $0.02 per common share) for the same period of 2020.

    AEZS: Business Highlights

    Alongside the operational results, AEZS also reported recent business highlights. The company had entered into an exclusive license with Julius-Maximilians-University of Wuerzburg. The license was about the early pre-clinical development of AIM Biologics which could prove handy in the treatment of Parkinson’s disease. The company also exercised its option to expand the application of the oral vaccine platform to chlamydia under the agreement.

    Executive Commentary

    Dr. Klaus Paulini, Chief Executive Officer of AEZS, while commenting on the results said that since the start of the year, the company had concerted efforts not only to advance its clinical-stage program but also to expand its development pipeline. He said that the company is diligently working to execute the advancements of all its clinical and pre-clinical programs and is poised to continue building value in the long term.

    Future Outlook for AEZS

    During the last three months, AEZS stock has declined more than 30%. However, recent performances depict that the stock is a hot and popular entity among investors. So, potential investors should keep a close eye on the developments related to AEZS stock to reap the upcoming benefits.

  • BeyondSpring Inc. (BYSI) Stock on a Consistent Rise, Here’s Why

    BeyondSpring Inc. (BYSI), a clinical-stage biopharmaceutical company, has surged 11.90% in aftermarket trading session. Consequently, BYSI stock is trading at $14.86 at the time of the writing. On Thursday, BYSI closed the day at $13.28 after gaining an increase of 4.90% during the mid-day session. The constant increase is attributable to the anticipated US FDA approval of Plinabulin, the company’s lead product and elective immunomodulating microtubule-binding agent (SIMBA). For the moment, let’s discuss some recent developments related to BYSI stock.

    BYSI Q2 2021 Financial Highlights

    On 10th September, BYSI released the financial results for the second quarter of the fiscal year 2021. The quarter ended on 30th June 2021. The company had cash and cash equivalents of $51.30 million on 30th June 2021. The total revenue generated by the company during the period was $0.33 million. The loss suffered from operations by the company during the period was $19.97 million against $13.61 million for the same period of 2020. The net loss bore by the company during the period was $19.89 million against $13.59 million for the same period of 2020. The net loss per basic and diluted share for the quarter was $0.46 against $0.49 for the same quarter of 2020.

    Upcoming Milestones

    Alongside the financial results, BYSI also shed a light on the upcoming milestones. The company said that 30th November 2021 would be the PDUFA date for the Plinabulin in CIN prevention. During fiscal 2022, the company expected Phase 2 Data plinabulin, nivolumab, and pilimumab in checkpoint inhibitor-resistant SCLC. During the first half of fiscal 2022, the company expected to achieve NDA Submission for plinabulin in NSCLC.

    Executive Commentary

    Dr. Lan Huang, co-founder, chairwoman, and chief executive officer of BYSI, while commenting on the results said that the company had a very productive first half of fiscal 2021 as it obtained positive data from the registrational trial of plinabulin in 2nd/3rd line NSCLC. He hoped that the company is truly on the cusp of unlocking the tremendous potential of plinabulin to help many patients in need.

    Future Outlook for BYSI

    During the last three months, BYSI stock has declined more than 55%, the prime reason being the uncertainty associated with the company’s product, Plinabulin. With the FDA approval, however, chances are that the stock starts capturing the investor interest in a short time.

  • HP Inc. (HPQ) Stock on a Rally in Aftermarket, Here’s the Reason

     HP Inc. (HPQ), a company providing personal computing and other access devices, imaging and printing products, and related technologies, is changing hands at $34.60 in aftermarket trading session after surging 7.49%. The increase could be attributed to the announcement of quarterly results by the company. HPQ stock closed Tuesday’s regular trading session at $32.19 after gaining an increase of 0.81%.

    Why HPQ on Rise?

    On Tuesday, HPQ announced the financial results for the fourth quarter of the fiscal year 2021. The quarter ended on 31st October 2021. The company generated net revenue of $16.67 billion during the quarter against $15.25 billion for the same quarter of 2020. The total costs and expenses bore by the company during the quarter were $15.43 billion against $14.26 billion for the same quarter of 2020. The net income generated by the company during the three months was $3.09 billion against $1.10 billion for the same period of 2020. The net earnings per basic and diluted share for the quarter were $2.75 and $2.71 against $0.50 and $0.49 for the same quarter of 2020.

    Outlook for Fiscal 2022

    HPQ also released the outlook for the upcoming quarter and fiscal alongside the financial results. The company estimated that for fiscal 2022, the GAAP diluted net EPS to be in the range of $0.99 to $1.05. The GAAP diluted net EPS for fiscal 2022 was estimated to be in the range of $4.07 to $4.27. The company anticipates that it could generate a net cash flow of $4.5 billion (minimum) during fiscal 2022.

    Executive Commentary

    Enrique Lores, CEO of HPQ, while commenting on the results said that the results depict a strong performance throughout the quarter and year by the company. He further said that the outstanding results depict the working environment of the company, which prefers cooperation instead of competition. He hoped that the company would be able to reproduce similar, or even better, results during the upcoming fiscal year.

    What Lies Ahead for HPQ?

    Stats reveal that HPQ stock has mostly seen positive times during the last 12 months. The prime reason for that is the market reputation of the company as among the best developers of computing devices. Analysts believe that the stock is well on track to achieve similar performance in the future to come.

  • Here’s the Reason Why the Gap, Inc. (GPS) Stock is Plunging in Aftermarket

    The Gap, Inc. (GPS), an apparel retail company, has plunged 16.21% in aftermarket trading session. As a result, GPS stock is trading at $19.70 at the time of the writing. The dip is attributable to the announcement of quarterly results by the company. On Tuesday, GPS stock closed the day at $23.51 after declining 1.80% during regular trading hours.

    Why GPS Dipping?

    On Tuesday, GPS released the financial results for the third quarter of the fiscal year 2021. The quarter ended on 30th October 2021. The company had cash and cash equivalents of $801 million on 30th October 2021. The net sales by the company during the period were $3.94 billion against $3.99 billion for the same period of 2020. The total operating expenses for the period were $1.5 billion against $1.44 billion for the same period of 2020. The company suffered a net loss of $152 million during the quarter against the net income of $95 million for the same quarter of 2020. The loss per basic and diluted share for the quarter was $0.40 against the income per share of $0.25 for the same quarter of 2020.

    Outlook for Fiscal 2021

    Alongside the financial results, GPS also released the outlook for the full year 2021. The company has said that the adjusted diluted earnings per share for the full year 2021 to be in the range of $1.25 to $1.40. The lost sales of $550 million to $650 million are also included in the outlook based on the supply chain constraints. The company has also included $450 million of total air freight expenses for the year. The company expects that the reported operating margin for the fiscal year 2021 to be 4.5%.

    Executive Commentary

    Katrina O’Connell, Executive Vice President and Chief Financial Officer of GPS, while commenting on the results said that while there is still hard work to be done to navigate the near term challenges in the macro-environment, the company has made tremendous progress, as evident from the quick adaptation in different domains. She further said that the company has a strong demand for its brand and its fleet’s rationalization and divestitures are progressing well and adding value in this regard.

    What’s Ahead for GPS Stock?

    A closer look a statistics reveals that GPS stock has not endured much volatility during the last 12 month period. That is a good sign, keeping in view the impacts pandemic has imparted its influence on the market. Analysts have advised potential investors to keep a close eye on the fluctuations of GPS stock to make informed decisions regarding their investments.